ArticleCancer prevention research (Philadelphia, Pa.)2015
Emergence of HPV16-positive oropharyngeal cancer in Black patients over time: University of Maryland 1992-2007.
Article in Cancer prevention research (Philadelphia, Pa.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The importance of HPV testing in oropharyngeal cancer in two US populations.Neoplasia (New York, N.Y.) · 2026Article
- Genotyping HPV 16 and 18 in oral and oropharyngeal cancer: uncovering HIV as a key risk factor in a Ugandan cohort.Infectious agents and cancer · 2025Article
- Disparities in head and neck cancer incidence and trends by race/ethnicity and sex.Head & neck · 2023Article
- Prevalence of human papillomavirus in head and neck cancers at tertiary care centers in the United States over time.Cancer · 2022Article
- Epidemiology of HPV Related Malignancies.Seminars in radiation oncology · 2021Review
- Adherence to Guideline-Concordant Care and Its Effect on Survival in Black Patients with Head and Neck Cancers: A SEER-Medicare Analysis.The oncologist · 2021Article
- The prevalence and genotyping of human papillomavirus in patients with oral tumors in health centers and clinics of Mazandaran in Iran.Virusdisease · 2018Article
- Review
- Measures of economic advantage associated with HPV-positive head and neck cancers among non-Hispanic black and white males identified through the National Cancer Database.Cancer epidemiology · 2017Article
- Article
- The complex relation between race, sex, and human papillomavirus status in head and neck cancer.Cancer · 2017Article
- Prevalence of HPV Infection in Racial-Ethnic Subgroups of Head and Neck Cancer Patients.Carcinogenesis · 2017Article
- Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method.JAMA oncology · 2017Article
- Racial differences in head and neck squamous cell carcinomas among non-Hispanic black and white males identified through the National Cancer Database (1998-2012).Journal of cancer research and clinical oncology · 2016Article
- Next-Generation Sequencing-Based HPV Genotyping Assay Validated in Formalin-Fixed, Paraffin-Embedded Oropharyngeal and Cervical Cancer Specimens.Journal of biomolecular techniques : JBT · 2016Article
- Article
- Transforming Cancer Prevention through Precision Medicine and Immune-oncology.Cancer prevention research (Philadelphia, Pa.) · 2016Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
While we previously reported a striking racial difference in the prevalence of human papilloma virus (HPV)-positive squamous cell carcinoma of the oropharynx (OPSCC), less is known about differences in outcomes and trends over time in OPSCC by HPV status and race. We conducted a retrospective analysis of 467 patients with OPSCC treated at the University of Maryland Greenebaum Cancer Center (Baltimore, MD) between 1992 and 2007, of which 200 had tissue available for HPV16 testing. HPV16-positive patients were significantly more likely to be white, with 45.5% of whites and 15.5% of blacks testing positive for HPV16. There was a significant increase in HPV16-positive OPSCC for all patients over time from 15.6% in 1992 to 1995 to 43.3% in 2004 to 2007 (P = 0.01). From 1992 to 1995, 33% of white patients were HPV16-positive, with no black patients positive. From 2004 to 2007, 17.7% of black patients and 54% of white patients were HPV16-positive. White and black patients with HPV16-positive tumors had an identical and favorable overall survival (OS; median, 8.1 and 8.1 years, respectively). However, among HPV16-negative patients, whites had an improved OS compared with blacks (median, 2.3 vs. 0.9 years, respectively; P = 0.02), including when analyzed in a multivariable Cox regression model. From 1992 to 2007, the percentage of HPV16-positive OPSCC increased for white patients and was seen for the first time in black patients. While survival for HPV-positive black and white patients was similar and favorable, outcomes for HPV-negative patients were poor, with blacks having worse survival even after controlling for baseline characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.